H.R. 383 · 118th Congress

To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.

Stage
In committee
Sponsor
Diana Harshbarger
Introduced
2023-01-17
Latest action
2023-01-27 · Referred to the Subcommittee on Health.

Action history

  1. 2023-01-27Referred to the Subcommittee on Health.
  2. 2023-01-17Introduced in House
  3. 2023-01-17Referred to the House Committee on Energy and Commerce.